R&D Trends

AMRA, BioTelemetry partner on NASH/NAFLD clinical trials

Friday, October 20, 2017

AMRA, the international leader in body composition analysis, and BioTelemetry Research (BTR), a global imaging and cardiac core lab, announced the formation of an exclusive alliance for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) clinical trials. This first-to-market partnership will advance imaging science and benefit clinical trial sponsors in several musculoskeletal and metabolic therapeutic areas.

[Read More]

Institut Curie, Pierre Fabre Partner on immuno-oncology

Friday, October 20, 2017

Institut Curie and the IRPF (Institut de Recherche Pierre Fabre) will collaborate on new therapeutic strategies to advance cancer treatment for patients. The objective of this novel partnership is to dissect the biology of novel therapeutically tractable targets and evaluate the impact of innovative pharmacological approaches leveraging the Institut Curie’s biological models.

[Read More]

Warp Drive Bio to combat multi-drug-resistant bacterial infections

Tuesday, October 17, 2017

Warp Drive Bio, a drug discovery company developing therapeutics that exploit the molecules and mechanisms of nature, has formed a strategic collaboration with Roche to discover and develop multiple novel classes of antibiotics. The serious global health threat of multi-drug-resistant bacterial infections has created an urgent need for new antibiotics with novel structures and mechanisms of action.

[Read More]

NIH partners with 11 biopharmaceutical companies on cancer immunotherapy strategies

Friday, October 13, 2017

The NIH and 11 biopharmaceutical companies launched the Partnership for Accelerating Cancer Therapies (PACT), a five-year public-private research collaboration totaling $215 million as part of the Cancer Moonshot. PACT will initially focus on efforts to identify, develop and validate robust biomarkers—standardized biological markers of disease and treatment response—to advance new immunotherapy treatments that harness the immune system to attack cancer. The partnership will be managed by the Foundation for the National Institutes of Health (FNIH), with the Food and Drug Administration serving in an advisory role. 

[Read More]

Karyopharm, Ono ink $193M deal

Friday, October 13, 2017

Karyopharm Therapeutics and Ono Pharmaceutical announced their entry into an exclusive license agreement for the development and commercialization of selinexor, Karyopharm’s lead, novel, oral Selective Inhibitor of Nuclear Export (SINE) compound, and KPT-8602, Karyopharm’s second-generation oral SINE compound. The agreement includes the development of selinexor and KPT-8602 for the diagnosis, treatment and/or prevention of all human oncology indications in Japan, South Korea, Taiwan, Hong Kong and ASEAN countries (the Territory).

[Read More]

Stand Up To Cancer awards Moffitt $2.67M to study lung cancer immunotherapy

Friday, October 13, 2017

Moffitt Cancer Center was awarded a $2.67 million grant from Stand Up To Cancer (SU2C) to study a possible new immunotherapy for non-small cell lung cancer. This is one of 10 first-of-its-kind grants being awarded by the SU2C Catalyst program. Under the program, pharmaceutical companies donate funds to support collaborative team research using products provided by the companies, such as compounds and agents in development or approved for investigational use. The Moffitt study will be in partnership with Bristol-Myers Squibb, with additional assistance from Iovance and Prometheus Laboratories.

[Read More]

LEO Science & Tech Hub, Elektrofi collaborate on dermatological drug delivery

Wednesday, October 11, 2017

LEO Science & Tech Hub, an R&D unit of LEO Pharma dedicated to identifying, developing, and funding innovative solutions that improve the lives of people with skin diseases, announced a collaboration agreement with Elektrofi, a Cambridge-based biotechnology company focused on drug delivery innovations, to explore advanced formulation technology for dermatological drug delivery. 

[Read More]